11.78
0.67%
-0.08
Amicus Therapeutics Inc stock is currently priced at $11.78, with a 24-hour trading volume of 2.46M.
It has seen a -0.67% decreased in the last 24 hours and a -9.03% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $11.68 pivot point. If it approaches the $12.04 resistance level, significant changes may occur.
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Amicus Therapeutics Inc (FOLD) Revenue 2023
FOLD reported a revenue (TTM) of $399.36 million for the quarter ending December 31, 2023, a +21.30% rise year-over-year.
Amicus Therapeutics Inc (FOLD) Net Income 2023
FOLD net income (TTM) was -$151.58 million for the quarter ending December 31, 2023, a +35.92% increase year-over-year.
Amicus Therapeutics Inc (FOLD) Cash Flow 2023
FOLD recorded a free cash flow (TTM) of -$76.53 million for the quarter ending December 31, 2023, a +55.07% increase year-over-year.
Amicus Therapeutics Inc (FOLD) Earnings per Share 2023
FOLD earnings per share (TTM) was -$0.51 for the quarter ending December 31, 2023, a +37.80% growth year-over-year.
Amicus Therapeutics Inc Stock (FOLD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
SBLENDORIO GLENN | Director |
Mar 07 '24 |
Option Exercise |
2.80 |
15,000 |
42,000 |
83,596 |
RAAB MICHAEL | Director |
Mar 05 '24 |
Option Exercise |
2.80 |
15,000 |
42,000 |
83,596 |
MCGLYNN MARGARET G | Director |
Mar 05 '24 |
Option Exercise |
2.80 |
7,500 |
21,000 |
66,789 |
MCGLYNN MARGARET G | Director |
Mar 05 '24 |
Sale |
13.40 |
7,500 |
100,500 |
59,289 |
MCGLYNN MARGARET G | Director |
Mar 04 '24 |
Option Exercise |
2.80 |
7,500 |
21,000 |
66,789 |
MCGLYNN MARGARET G | Director |
Mar 04 '24 |
Sale |
13.29 |
7,500 |
99,675 |
59,289 |
Campbell Bradley L | President and CEO |
Mar 01 '24 |
Option Exercise |
10.54 |
15,833 |
166,904 |
887,052 |
Crowley John F | Executive Chairman |
Mar 01 '24 |
Sale |
13.35 |
29,181 |
389,543 |
573,478 |
Campbell Bradley L | President and CEO |
Mar 01 '24 |
Sale |
13.14 |
15,833 |
208,017 |
871,219 |
Crowley John F | Executive Chairman |
Feb 15 '24 |
Sale |
13.81 |
31,614 |
436,551 |
697,628 |
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Zacks Investment Research
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
GlobeNewswire Inc.
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
GlobeNewswire Inc.
Time to Buy These 3 Healthcare Companies That Raised Revenue Guidance?
Investing.com
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
Zacks Investment Research
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Cap:
|
Volume (24h):